Table 1 Clinicopathological characteristics of trials included
Study | Country | Study year | Design of studies | Follow-up(months) | Tumor type | PTBD | EBD | Outcome indicators | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. | TBIL (mg/dl) | Histologic grade | Tumor location | No. | TBIL (mg/dl) | Histologic grade | Tumor location | |||||||
Poorly differentiated | Poorly differentiated | |||||||||||||
Kawakami et al. [10] | Japan | 1999–2009 | RCS | 60 | PHC | 48 | 12.0 | – | I 4 II 12 IIIa 8 IIIb 8 IV 16 | 80 | 9.6 | – | I 15 II 22 IIIa 16 IIIb 11 IV 16 | ①, ② |
Hwang et al. [19] | Korea | 1985–2002 | RCS | 120 | PHC | 171 | – | – | – | 62 | – | – | – | ①, ② |
Murakami et al. [11] | Japan | 1998–2013 | RCS | 60 | PC | 20 | – | 14 | – | 73 | – | 47 | – | ①, ②, ③ |
Hirano et al. [12] | Japan | 2000–2008 | RCS | 160 | PHC | 67 | 8.4 | – | I 5 II 16 IIIa 13 IIIb 13 IV 20 | 74 | 5.2 | – | I 15 II 21 IIIa 12 IIIb 16 IV 10 | ①, ②, ③ |
Komaya et al. [13] | Japan | 2001–2010 | RCS | 60 | DCC | 189 | 7.4 | 117 | Middle 53 Low 136 | 187 | 4.7 | 123 | Middle 61 Low 126 | ①, ②, ③ |
Uemura et al. [14] | Japan | 2001–2012 | RCS | 120 | PC | 166 | – | 163 | – | 407 | – | 392 | – | ①, ②, ③, ④ |
Wiggers et al. [18] | Netherland/USA | 1991–2012 | RCS | 60 | PC | 88 | 11.2 | – | I 8 II 11 IIIa 30 IIIb 18 IV:19 | 157 | 3.2 | – | I 41 II 23 IIIa 44 IIIb 28 IV 16 | ①, ③ |
Komaya et al. [15] | Japan | 2003–2012 | RCS | 60 | PHC | 168 | – | 123 | I/II/III 77 IV 91 | 152 | – | 113 | I/II/III 92 IV 60 | ①, ②, ③ |
Higuchi et al. [16] | Japan | 2000–2013 | RCS | 12~60 | PHC | 87 | – | 58 | I/II/III 50 IV 37 | 76 | – | 52 | I/II/III 44 IV 32 | ①, ② |
Miura et al. [17] | Japan | 1987–2015 | RCS | 60 | DCC | 25 | 3.7 | 12 | – | 63 | 2.4 | 32 | – | ①, ② |